



NDA 21227/S-030

**SUPPLEMENT APPROVAL**

Merck Sharp & Dohme Corp.  
Attention: Vamsidhara Dhulipala, B.V.Sc; Ph.D.  
Director, Global Regulatory Affairs  
P.O. Box 1000, UG2D-68  
North Wales, PA 19454-2505

Dear Dr. Dhulipala:

Please refer to your Supplemental New Drug Application (sNDA) dated March 16, 2012, received March 16, 2012, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Cancidas (caspofungin acetate) Injection, 50 mg/vial and 70 mg/vial.

We acknowledge receipt of your amendments dated June 21, 2012, and January 22, June 17, and July 30, 2013.

This "Prior Approval" supplemental new drug application provides for revisions to the CLINICAL PHARMACOLOGY Section (12), Microbiology subsection (12.4) of the package insert regarding susceptibility interpretive criteria.

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

**CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the package insert), with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that includes labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

### **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Alison Rodgers, Regulatory Project Manager, at (301) 796-0797.

Sincerely,

*{See appended electronic signature page}*

Sumathi Nambiar, MD, MPH  
Acting Director  
Division of Anti-Infective Products  
Office of Antimicrobial Products  
Center for Drug Evaluation and Research

ENCLOSURE:  
Content of Labeling

-----  
**This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.**  
-----

/s/  
-----

SUMATHI NAMBIAR  
08/02/2013